Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, PO Box 30.0001, 9700, RB, Groningen, The Netherlands.
Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, PO Box 30.0001, 9700, RB, Groningen, The Netherlands.
Respir Res. 2018 Dec 18;19(1):256. doi: 10.1186/s12931-018-0961-2.
We performed a post-hoc analysis of the OLiVIA-study investigating whether current and ex-smoking asthmatics with small airways dysfunction (SAD) show a better response in airway hyperresponsiveness (AHR) to small particle adenosine after treatment with extrafine compared to non-extrafine particle inhaled corticosteroids (ICS), and to investigate which clinical parameters predict a favorable response to both treatments. We show that smoking and ex-smoking asthmatics with and without SAD have a similar treatment response with either extrafine or non-extrafine particle ICS. We also found that lower blood neutrophils are associated with a smaller ICS-response in smokers and ex-smokers with asthma, independent from the level of blood eosinophils.
我们对 OLiVIA 研究进行了一项事后分析，旨在探讨小气道功能障碍 (SAD) 的当前和既往吸烟哮喘患者在接受超细与非超细颗粒吸入皮质类固醇（ICS）治疗后，对小颗粒腺苷诱导的气道高反应性 (AHR) 是否有更好的反应，并探讨哪些临床参数可预测对两种治疗均有良好反应。我们表明，有和没有 SAD 的吸烟和既往吸烟哮喘患者对超细或非超细颗粒 ICS 的治疗反应相似。我们还发现，无论血嗜酸性粒细胞水平如何，吸烟者和既往吸烟者的血中性粒细胞越低，ICS 反应越小。
